Relief or Risk? Triptans, Migraines, and SCAD Authors: Maryam Taheri, Marysia S Tweet Published: 2026 ABSTRACT Corresponding AuthorKey Words: cardiac assist devices, coronary angiography, left-sided catheterization, left ventricle, myocardial infarction, myocardial revascularization, percutaneous coronary intervention, stents Over the past decade, spontaneous coronary artery dissection (SCAD) has emerged as notable cause of acute coronary syndrome (ACS) in young and middle-aged women. Despite recent advances, questions remain regarding disease triggers, associated vascular phenotypes, and mechanisms underlying acute events.1 In this issue of JACC: Case Reports, Kyhan et al2 describe a striking case of left main SCAD presenting shortly after sumatriptan exposure in a 33-year-old woman with migraine. The patient developed ST-segment elevation myocardial infarction due to SCAD treated with percutaneous coronary intervention (PCI); ventricular fibrillation and cardiogenic shock requiring venoarterial extracorporeal membrane oxygenation and Impella support; and downstream complications including ischemic stroke and spinal cord infarction. Despite an extraordinarily complicated hospital course, meaningful cardiac recovery was achieved. Several aspects of this report deserve attention. First, the case highlights the heterogeneous and occasionally catastrophic presentation of SCAD. Although most SCADs can be managed conservatively, a critical subgroup has high-risk features including left main involvement, ongoing ischemia, malignant ventricular arrhythmias, or cardiogenic shock.1 In such situations, revascularization and mechanical circulatory support may be lifesaving. This report reminds us that treatment should be individualized to the clinical status with the goal of saving the patient. Second, this report demonstrates the vicious cycle of clotting and bleeding, especially in menstruating women. Two observational studies of conservatively managed SCAD patients have shown that early dual antiplatelet therapy (DAPT), rather than single antiplatelet therapy, is associated with increased risk of adverse events.3,4 This is hypothesized due to expansion of the coronary hematoma.5 However, DAPT remains important post PCI, acknowledging the bleeding risk. This patient was treated with DAPT and heparin in the context of PCI, extracorporeal membrane oxygenation, and Impella. However, this contributed to a bleeding-clotting paradox, and she developed severe vaginal bleeding, femoral and popliteal artery thromboses, stroke due to M1 occlusion, bilateral subdural hematomas, and spinal cord infarction. It is critical that the team is ready to respond to such complications and that the patient and family are counseled accordingly. In this case, intracoronary imaging confirmed the diagnosis and guided care; however, it should be used thoughtfully due to risk for SCAD propagation.6 Repeat invasive coronary angiography to assess for healing—because atherosclerotic plaque will not heal whereas SCAD hematoma usually resolves—is another tool to confirm ACS etiology but should not be performed routinely. The role of coronary computed tomography angiography for SCAD re-assessment is emerging as a viable noninvasive option, especially with the enhanced resolution provided by photon-counting coronary computed tomography angiography. The biologic basis for the recognized association between migraine and SCAD remains uncertain but proposed mechanisms include endothelial dysfunction, abnormal vascular reactivity, shared genetic susceptibility, and a broader systemic arteriopathy.7,8 The temporal relationship between sumatriptan administration and symptom onset in this case is compelling. Triptans are selective serotonin 5-HT1B/1D receptor agonists that exert therapeutic effects through cranial vasoconstriction, inhibition of vasoactive neuropeptides and nociceptive neurotransmitters, disruption of nitric oxide pathways, and inhibition of neurogenic inflammation.9 Their vasoconstrictive properties have long prompted caution in patients with known coronary artery disease.10 Case reports have documented coronary vasospasm, myocardial infarction, and, rarely, cardiac arrest following triptan exposure.11,12 Furthermore, pharmacovigilance analyses have suggested a potential signal linking triptan use and SCAD.13 These observations are compelling but do not establish a direct mechanistic link. Migraine itself is highly prevalent among patients with SCAD, creating confounding.7,8 It is possible that the triptan exposure was coincidental. Regardless, this extreme case raises broader questions regarding migraine management after SCAD. Current evidence is insufficient to support universal avoidance of triptans in all patients with migraine. Given the pharmacovigilance signal and biologic plausibility, the avoidance of triptans is reasonable in patients with previous SCAD and supported by expert consensus.1 Promising alternative options include calcitonin gene-related peptide–targeted therapies, nonvasoconstrictive 5-HT1F serotonin receptor antagonists, and botulism toxin injections.10 Ultimately, this patient case highlights an intriguing and clinically relevant intersection among migraine, vasoactive therapy, and SCAD. For clinicians, the message is clear: SCAD should be high on the differential diagnosis of ACS in young women, and alternatives to triptans are preferred (Figure 1). For investigators, the challenge remains to understand the mechanism of SCAD and learn how to predict and prevent future ACS in vulnerable populations. Key Takeaways Graphic created by the authors using generative artificial intelligence (ChatGPT). ACS = acute coronary syndrome; SCAD = spontaneous coronary artery dissection. Funding Support and Author Disclosures Dr Tweet is supported by the National Heart, Lung, and Blood Institute, National Institutes of Health (K23HL155506), Bethesda, Maryland, USA. The Mayo Clinic SCAD Research Program is supported by SCAD Research, Inc. Dr Taheri has reported that she has no relationships relevant to the contents of this paper to disclose. Footnotes The authors attest they are in compliance with human studies committees and animal welfare regulations of the authors’ institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the Author Center. References